Results 171 to 180 of about 2,343,487 (194)

Hepatocyte Growth Hormone Receptor Ablation Is Associated With Aging Phenotypes and Hepatic Mitochondrial Dysfunction

open access: yesAging Cell, Volume 25, Issue 10, October 2026.
Hepatocyte‐specific GHR ablation is associated with hepatic and age‐related pathologies, triggering adipose‐liver crosstalk via elevated circulating GH and subsequent CD36‐dependent hepatic steatosis. This loss impairs STAT5b phosphorylation and enhances PPARγ nuclear activation, upregulating Pdk4 and Cd36 to drive mitochondrial dysfunction and ectopic
Kangkang Yang   +7 more
wiley   +1 more source

Zeb2 Controls Retinal Physiological and Pathological Angiogenesis by Regulating Astrocyte Proliferation and Differentiation

open access: yesCell Proliferation, Volume 59, Issue 10, October 2026.
During development, the oxygen‐sensitive transcription factor Zeb2 restrains astrocyte proliferation and maturation to ensure balanced retinal angiogenesis. In disease, it promotes the neurotoxic A1 astrocyte phenotype and inflammation, thereby promoting reparative revascularization over pathological neovascularization.
Jing Liu   +5 more
wiley   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

open access: yesClinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju   +6 more
wiley   +1 more source

Cancer Evolvability Determines Therapy Outcomes

open access: yesEvolutionary Applications, Volume 19, Issue 10, October 2026.
ABSTRACT Cancer progression following treatment failure is an evolutionary process in which therapy acts as a selection pressure driving Darwinian selection on heritable variation to favor resistant clones. Heritable variation is a key determinant of how rapidly tumors can adapt to therapy.
Ranjini Bhattacharya   +3 more
wiley   +1 more source

Negotiating Reproductive Identity After Cancer: A Qualitative Systematic Review of Female Survivors' Post‐Treatment Fertility Experiences

open access: yesHealth Expectations, Volume 29, Issue 5, October 2026.
ABSTRACT Background Fertility concerns are common among female cancer survivors and are shaped by sociocultural influences that extend beyond biomedical outcomes. Previous systematic reviews have consolidated evidence on fertility‐related distress but have tended to operate within clinical or descriptive frameworks.
Yijun Wang   +3 more
wiley   +1 more source

Effects of short‐course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor‐positive, HER2‐negative breast cancer

open access: yesHistopathology, Volume 89, Issue 4, Page 670-686, October 2026.
Short‐course preoperative endocrine therapy induces histopathological and immunophenotypic changes in oestrogen receptor‐positive, HER2‐negative breast cancer. Proliferative response is independently associated with baseline genomic risk (MammaPrint) and progesterone receptor expression.
Claudia Grosse   +8 more
wiley   +1 more source

Protein O‐Glycosylation Shapes Lymphatic Endothelia and Lymph Node Macrophage Populations

open access: yesThe FASEB Journal, Volume 40, Issue 18, 30 September 2026.
To study the functional roles of O‐glycans on lymphatic endothelia, we deleted Cosmc, the chaperone required for core‐1 O‐glycan synthesis. Loss of core‐1 O‐glycans entailed major changes in glycoprotein composition of lymphatic endothelial cells (LEC), including reduced podoplanin (Pdpn), CD44, and Lyve‐1, and increased ICAM‐1; reduced CD44 was caused
Jasmin Frey   +11 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Top bar navigation

Frontiers in Pharmacology, 2020
Jianhong Zuo, Jingwei Yao, Jialu Huang
exaly  

Home - About - Disclaimer - Privacy